The presence of anti-ficolin 3 antibodies could be used as a biomarker to diagnose active lupus with kidney involvement according to a study published in the scientific journal Plos One.
The results of a Phase 2/3 trial at two hospitals in the U.K. comparing the effectiveness of Xarelto (rivaroxaban) and Coumadin (warfarin) in the treatment of patients with thrombotic antiphospholipid syndrome (APS), with or without systemic lupus erythematosus, showed that Xarelto can be a safe and effective option for patients with…
A recent study published in the journal Health and Quality of Life Outcomes revealed that the Brief Resilient Coping Scale (BRCS) is a suitable tool to assess resilience in patients with systemic lupus erythematosus (SLE). The BRCS is a self-reported measurement test considered a reliable indicator of resilience — the ability to cope…
Kezar Life Sciences, a San Francisco-based company focused on the development of therapies targeting protein homeostasis, recently initiated a Phase 1 clinical trial assessing KZR-616, a potential treatment for multiple autoimmune and inflammatory diseases, including lupus. Together with a medical team in Australia, the study will be performed in a…
A large number of patients with class II lupus nephritis (LN) show histological transformations years after the diagnosis, a new study reported, adding that proteinuria — or excessive amounts of protein in the urine — can serve as a predictor of patient outcome. This findings are the result of a multicenter study carried out in…
The Pharmaceutical Research and Manufacturers of America (PhRMA) and Lupus Foundation of America (LFA) released a new report highlighting the progress in the fight against autoimmune diseases, including lupus. The report, “Medicines in Development for Autoimmune Diseases: A Report on Autoimmune Diseases,” states that America’s biopharmaceutical…
Leptin, a hormone produced by fat cells in the body, was seen to actively promote systemic lupus erythematosus (SLE) in mouse models of the disease, allowing the formation of autoantibodies and changing the activities of immune cells. Patients with lupus have increased levels of leptin, but until now researchers did not know…
In a recent update on its pivotal Phase 3 clinical trial evaluating Lupuzor (rigerimod) as a potential treatment for lupus, ImmuPharma announced that it was complying with a request to open a trial site in Mauritius so that patients there could participate in the study. According to the company, the leading…
XTL Biopharmaceuticals announced that a patent has been issued covering the Europe Union for its leading drug candidate, hCDR1 (edratide), a potential treatment for systemic lupus erythematosus (SLE). The European Patent Office issue (EP1594434) is titled “Parenteral Formulations of Peptides for the Treatment of Systemic Lupus Erythematosus,” and covers formulations…
Maintaining optimal levels of vitamin D in the blood could be protective against the risk of cardiovascular disease often seen in systemic lupus erythematosus (SLE) patients, according to a large literature review conducted on the subject.